TABLE 2.
Clinical characteristics of patients who did and did not receive induction chemotherapy
No. (%) | |||
---|---|---|---|
Characteristic | No induction chemotherapy | Induction chemotherapy | P |
Total | 358 | 204 | |
Tumor (T classification) | <.001 | ||
TO or Txa | 0 (0.0) | 2 (1.0) | |
T1 | 60 (16.8) | 19 (9.3) | |
T2 | 146 (40.8) | 44 (21.6) | |
T3 | 83 (23.2) | 64 (31.4) | |
T4 | 69 (19.3) | 75 (36.8) | |
Dental extraction | <.001 | ||
No | 254 (70.9) | 101 (49.5) | |
Yes | 104 (29.1) | 103 (50.5) | |
Alcohol use | .188 | ||
No | 138 (38.5) | 91 (44.6) | |
Yes | 220 (61.5) | 113 (55.4) | |
Smokingb | .070 | ||
No | 193 (53.9) | 93 (45.6) | |
Yes | 165 (46.1) | 111 (54.4) | |
Hypomagnesemia during treatment course | <.001 | ||
No | 224 (62.6) | 64 (31.4) | |
Yes | 134 (37.4) | 140 (68.6) | |
Hypomagnesemia grading | <.001 | ||
No hypomagnesemia | 224 (62.6) | 64 (31.4) | |
Grade 1 | 123 (34.4) | 127 (62.3) | |
Grade 2 and more | 11 (3.1) | 13 (6.4) | |
Frequency of hypomagnesemia (IQR) | 0 (0, 1) | 2 (0, 6) | <.001 |
Median radiation dose (IQR) | 70 Gy (66–70 Gy) | 70 Gy (70–70 Gy) | .032 |
Surgeryc | .198 | ||
No | 309 (86.3) | 167 (81.9) | |
Yes | 49 (13.7) | 37 (18.1) | |
ORN | .632 | ||
No | 295 (82.4) | 164 (80.4) | |
Yes | 63 (17.6) | 40 (19.6) | |
Cisplatin cumulative dose (mg) | 415 (348, 498) | 498 (360, 756) | <.001 |
Carboplatin cumulative dose (mg) | 1129 (762, 1498) | 1943 (1479, 3003) | <.001 |
Use of cetuximab | <.001 | ||
No | 357 (99.7) | 127 (62.3) | |
Yes | 1 (0.3) | 77 (37.7) | |
Use of PPI | .028 | ||
No | 302 (84.4) | 156 (76.5) | |
Yes | 56 (15.6) | 48 (23.5) | |
Use of diuretics | .027 | ||
No | 353 (98.6) | 194 (95.1) | |
Yes | 5 (1.4) | 10 (4.9) |
Note: The values marked in bold italics indicate statistical significance (P < .05).
Abbreviations: IQR, interquartile range; ORN, osteoradionecrosis.
Tx refers no primary tumor.
Nonsmoker or smoked less than 5 pack-year.
Head and neck surgery before radiation excluding biopsy and tonsillectomy.